A lipophilic farnesyl moiety attached to the carboxyl terminal cysteine of
ras proteins structurally supports their membrane anchorage, required for r
as-dependent growth-factor signaling and for transforming activity of ras o
ncoproteins. It has been shown that inhibition of ras farnesylation can blo
ck tumor growth in nude mice but that some ras-dependent tumors escape such
blockage as a result of prenylation of ras. S-trans-transfarnesylthiosalic
ylic acid (FTS) is a potent ras-dislodging antagonist that does not affect
ras prenylation but rather acts on the mature, membrane-bound ras and facil
itates its degradation. Here we demonstrate that FTS induces reappearance o
f stress fibers in H-ras-transformed rat-1 cells (EJ cells) in vitro, inhib
its their anchorage-independent growth in vitro, and blocks EJ-tumor growth
in nude mice. The anchorage-independent growth of cells expressing ErbB2 (
B104), but not that of v-raf-transformed cells, is also inhibited by FTS, s
uggesting specificity towards activated ras. FTS treatment (5 mg/kg i.p. da
ily) caused inhibition (75-80%) of tumor growth in nude mice implanted with
EJ, but not in mice implanted with v-raf-transformed cells, with no eviden
ce of systemic toxicity. Moreover, FTS treatment increased the survival rat
e of EJ-tumor-bearing mice from 48 to 68 days. Here we demonstrate anti-tum
or potency in a synthetic, non-toxic, ras dislodging antagonist acting inde
pendently of farnesyltransferases. Int. J. Cancer 80:911-918, 1999. (C) 199
9 Wiley-Liss, Inc.